Search company, investor...

Founded Year



Corporate Minority | Alive

Total Raised


Last Raised

$10M | 6 mos ago

About Pendulum

Pendulum develops personalized health solutions through microbiome diagnostics and intervention. It develops probiotic supplements and offers Akkermansia for gut health, metabolic daily for optimizing metabolism, Butyricum for occasional gut discomfort, and more. It was formerly known as Whole Biome. The company was founded in 2012 and is based in San Francisco, California.

Headquarters Location

933 20th Street

San Francisco, California, 94107,

United States




Expert Collections containing Pendulum

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pendulum is included in 2 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,958 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

Pendulum Patents

Pendulum has filed 24 patents.

The 3 most popular patent topics include:

  • microbiology
  • bacteriology
  • autosomal recessive disorders
patents chart

Application Date

Grant Date


Related Topics




G protein coupled receptors, Olfactory receptors, Psychiatric diagnosis, Autosomal recessive disorders, Rare diseases


Application Date


Grant Date



Related Topics

G protein coupled receptors, Olfactory receptors, Psychiatric diagnosis, Autosomal recessive disorders, Rare diseases



Latest Pendulum News

Pendulum Therapeutics Announces Strategic Partnership and $10M Investment from Fonterra

Jul 3, 2023

Pendulum Therapeutics Announces Strategic Partnership and $10M Investment from Fonterra Pendulum Therapeutics , the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra . Fonterra will invest $10 million into the growth-stage company to co-develop and commercialize next-generation microbiome products. The digestive health products market is exploding, sized at $51 billion globally (Source:  Grandview ). The strategic partnership leverages Fonterra’s innovation, manufacturing expertise, and long-standing leadership in global markets, alongside Pendulum’s deep science-backed innovation, microbiome expertise and category leadership in the U.S. probiotic market. The investment accelerates Pendulum’s ability to bring forward solutions that help people address gut microbiome deficiencies, which affect 40% of people globally ( Gastroenterology ). This investment from Fonterra, a $14 billion global company, signals that gut health is increasingly being recognized as an important factor in whole-body health and wellness,” said Colleen Cutclfife, Ph.D., CEO and Co-founder of Pendulum Therapeutics. Pendulum’s scientists are conducting cutting-edge microbiome research and developing products that have a meaningful and measurable impact on metabolic health for millions of people. This strategic partnership with Fonterra enables us to tap into their deep-rooted manufacturing expertise and established global presence to bring a new wave of microbiome products to market. The $10 million investment from Fonterra will come from their newly formed nutrition science venture arm, provisionally named Nutrition Science Solutions (NSS). NSS will incubate, invest in and scale ventures in the nutrition science field, and operate as a standalone business within Fonterra with its own board and CEO. The investment will also designate Fonterra as a minority shareholder in the San Francisco-based biotech company. As part of the strategic partnership, NSS and Pendulum will work together to co-develop and commercialize next-generation products that are scientifically formulated to make a measurable impact on people’s gut microbiome health, helping consumers overcome certain health conditions like immunity, mental health, cognitive health, and aging. Nutrition science is a segment of the global health and wellness category that goes beyond everyday lifestyle and wellness products, and we’re excited to tap into it more deeply through our partnership with Pendulum,” said Miles Hurrell, CEO of Fonterra. Our shared objective to bring proven, high impact health products to the world led us to partner with and invest in Pendulum. We’re confident that together we can deliver health solutions that make measurable improvements to people’s health around the world.”

Pendulum Frequently Asked Questions (FAQ)

  • When was Pendulum founded?

    Pendulum was founded in 2012.

  • Where is Pendulum's headquarters?

    Pendulum's headquarters is located at 933 20th Street, San Francisco.

  • What is Pendulum's latest funding round?

    Pendulum's latest funding round is Corporate Minority.

  • How much did Pendulum raise?

    Pendulum raised a total of $109.5M.

  • Who are the investors of Pendulum?

    Investors of Pendulum include Fonterra, Halle Berry, Felicis, True Ventures, Sequoia Capital and 8 more.

  • Who are Pendulum's competitors?

    Competitors of Pendulum include Caelus Health.


Compare Pendulum to Competitors

Caelus Health

Caelus Health operates as a biotechnology company. It develops microbiome therapeutics for the reduction of insulin resistance and prevention of type 2 diabetes (T2DM) in people with metabolic syndrome. The company is dedicated to the commercialization of functional food and pharma biotic products for the prevention and early treatment of cardiometabolic diseases based on the correlation between the intestinal microbiome and health. It was founded in 2015 and is based in Amsterdam, Netherlands.

MaaT Pharma Logo
MaaT Pharma

MaaT Pharma is a clinical-stage microbiome therapeutics company operating in the oncology sector. The company's main focus is on improving survival outcomes in life-threatening diseases, particularly blood cancers and graft-versus-host disease, by restoring patient-microbiome symbiosis. MaaT Pharma primarily serves the healthcare and pharmaceutical industries. It was founded in 2014 and is based in Lyon, France.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.